Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
Multiple myeloma (MM) is a genetically complex disease. The key myeloma-initiating genetic events are hyperdiploidy and translocations involving the immunoglobulin heavy chain (IgH) enhancer on chromosome 14, which leads to the activation of oncogenes (e.g., CCND1, CCND3, MAF, and MMSET). The t(11;1...
Main Authors: | Michael D. Diamantidis, Sofia Papadaki, Evdoxia Hatjiharissi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.934008/full |
Similar Items
-
The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
by: Kenneth JC Lim, et al.
Published: (2023-08-01) -
Evaluating the difference in clinical efficacy for t(11;14) multiple myeloma patients with CD20- or CD20+
by: ZHAO Weihong, HUANG Bintao, LIU Rui, XIANG Caixia
Published: (2023-09-01) -
CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
by: Yuan Jian, et al.
Published: (2022-12-01) -
The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma
by: Martina Kleber, et al.
Published: (2023-12-01) -
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity
by: Katia Todoerti, et al.
Published: (2021-09-01)